ATLANTA, GA (Globe Newswire – May 6, 2026) — Holzer & Holzer, LLC is investigating whether GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) complied with federal securities laws. On May 4, 2026, GeneDx reported its first quarter 2026 results and revised its guidance. Total revenue was $12 million lower than expected, which the Company attributed to: “mix dynamics resulting in a lower-than-expected blended average reimbursement rate and softer noncore business line performance.” The price of the Company’s stock dropped following this news.

If you purchased GeneDx stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/genedx-holdings/ to discuss your legal rights.